A strategy of being profitably smart and socially good to provide affordable access to advanced biopharmaceuticals for global patient populations.
A strategy of being profitably smart and socially good to provide affordable access to advanced biopharmaceuticals for global patient populations.
A motivation to enter niche areas where we perceive the potential to moderate costs and widen patient access.
A collaborative model that allows us to share risk and reward of drug development through research partnerships and extend our global footprint through local marketing alliances.
A business philosophy built around the core values of quality, affordability, reliability and innovation.
An unwavering commitment to stringent quality controls in compliance with best-in-class global standards.
A relentless focus on chronic disease spaces like diabetes, cancer and autoimmune / inflammation.
A portfolio approach focused on chronic disease segments and integrating well validated target-to-clinic-to-counter capabilities.
An obligation to develop affordable blockbuster drugs with the potential to benefit a billion patients.